378 related articles for article (PubMed ID: 35278677)
1. COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529) variant: a light at the end of the tunnel?
Mattiuzzi C; Henry BM; Lippi G
Int J Infect Dis; 2022 May; 118():167-168. PubMed ID: 35278677
[TBL] [Abstract][Full Text] [Related]
2. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022.
Rzymski P; Kasianchuk N; Sikora D; Poniedziałek B
J Med Virol; 2023 Jan; 95(1):e28131. PubMed ID: 36068643
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
Saxena SK; Kumar S; Ansari S; Paweska JT; Maurya VK; Tripathi AK; Abdel-Moneim AS
J Med Virol; 2022 Apr; 94(4):1738-1744. PubMed ID: 34905235
[TBL] [Abstract][Full Text] [Related]
6. Transmissibility, hospitalization, and intensive care admissions due to omicron compared to delta variants of SARS-CoV-2 in Catalonia: A cohort study and ecological analysis.
Català M; Coma E; Alonso S; Andrés C; Blanco I; Antón A; Bordoy AE; Cardona PJ; Fina F; Martró E; Medina M; Mora N; Saludes V; Prats C; Prieto-Alhambra D; Alvarez-Lacalle E
Front Public Health; 2022; 10():961030. PubMed ID: 36033822
[TBL] [Abstract][Full Text] [Related]
7. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.
Dhama K; Nainu F; Frediansyah A; Yatoo MI; Mohapatra RK; Chakraborty S; Zhou H; Islam MR; Mamada SS; Kusuma HI; Rabaan AA; Alhumaid S; Mutair AA; Iqhrammullah M; Al-Tawfiq JA; Mohaini MA; Alsalman AJ; Tuli HS; Chakraborty C; Harapan H
J Infect Public Health; 2023 Jan; 16(1):4-14. PubMed ID: 36446204
[TBL] [Abstract][Full Text] [Related]
8. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022.
Taylor CA; Whitaker M; Anglin O; Milucky J; Patel K; Pham H; Chai SJ; Alden NB; Yousey-Hindes K; Anderson EJ; Teno K; Reeg L; Como-Sabetti K; Bleecker M; Barney G; Bennett NM; Billing LM; Sutton M; Talbot HK; McCaffrey K; Havers FP;
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(12):466-473. PubMed ID: 35324880
[TBL] [Abstract][Full Text] [Related]
9. Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022.
Havers FP; Patel K; Whitaker M; Milucky J; Reingold A; Armistead I; Meek J; Anderson EJ; Weigel A; Reeg L; Seys S; Ropp SL; Spina N; Felsen CB; Moran NE; Sutton M; Talbot HK; George A; Taylor CA;
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(34):1085-1091. PubMed ID: 36006841
[TBL] [Abstract][Full Text] [Related]
10. Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.
Domínguez-Ramírez L; Solis-Tejeda I; Ayon-Aguilar J; Mayoral-Ortiz A; Sosa-Jurado F; Pelayo R; Santos-López G; Cortes-Hernandez P
Front Public Health; 2022; 10():1010256. PubMed ID: 36176536
[TBL] [Abstract][Full Text] [Related]
11. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study.
Jassat W; Abdool Karim SS; Mudara C; Welch R; Ozougwu L; Groome MJ; Govender N; von Gottberg A; Wolter N; Wolmarans M; Rousseau P; ; Blumberg L; Cohen C
Lancet Glob Health; 2022 Jul; 10(7):e961-e969. PubMed ID: 35597249
[TBL] [Abstract][Full Text] [Related]
12. Severity of the Omicron SARS-CoV-2 variant compared with the previous lineages: A systematic review.
Arabi M; Al-Najjar Y; Mhaimeed N; Salameh MA; Paul P; AlAnni J; Abdelati AA; Laswi I; Khanjar B; Al-Ali D; Elshafeey A; Mhaimeed O; Burney Z; D'Souza A; Sinha P; Bhatti M; Pillai KV; Homssi M; Bshesh K; Yagan L; Zakaria D
J Cell Mol Med; 2023 Jun; 27(11):1443-1464. PubMed ID: 37203288
[TBL] [Abstract][Full Text] [Related]
13. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines.
Araf Y; Akter F; Tang YD; Fatemi R; Parvez MSA; Zheng C; Hossain MG
J Med Virol; 2022 May; 94(5):1825-1832. PubMed ID: 35023191
[TBL] [Abstract][Full Text] [Related]
14. Differences in incidence and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in relation to vaccine coverage: A world-wide review.
Wang C; Liu B; Zhang S; Huang N; Zhao T; Lu QB; Cui F
J Med Virol; 2023 Jan; 95(1):e28118. PubMed ID: 36056540
[TBL] [Abstract][Full Text] [Related]
15. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
Yu X; Qi X; Cao Y; Li P; Lu L; Wang P; Feng Y; Yang J; Wei H; Guo L; Sun M; Liu Q; Lv J; Feng Y
Emerg Microbes Infect; 2022 Dec; 11(1):749-752. PubMed ID: 35176972
[TBL] [Abstract][Full Text] [Related]
16. Is the SARS CoV-2 Omicron Variant Deadlier and More Transmissible Than Delta Variant?
Duong BV; Larpruenrudee P; Fang T; Hossain SI; Saha SC; Gu Y; Islam MS
Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457468
[TBL] [Abstract][Full Text] [Related]
17. Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 - February 2022).
Petrone D; Mateo-Urdiales A; Sacco C; Riccardo F; Bella A; Ambrosio L; Lo Presti A; Di Martino A; Ceccarelli E; Del Manso M; Fabiani M; Stefanelli P; Pezzotti P; Palamara A;
Int J Infect Dis; 2023 Apr; 129():135-141. PubMed ID: 36708869
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Omicron variant: recent progress and future perspectives.
Fan Y; Li X; Zhang L; Wan S; Zhang L; Zhou F
Signal Transduct Target Ther; 2022 Apr; 7(1):141. PubMed ID: 35484110
[TBL] [Abstract][Full Text] [Related]
19. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
Bui NN; Lin YT; Huang SH; Lin CW
Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.
CDC COVID-19 Response Team
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(50):1731-1734. PubMed ID: 34914670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
